Get the latest news, insights, and market updates on CV (CapsoVision, Inc.). Explore the news page 1 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.
November 2025's High Growth Companies With Insider Influence
As the U.S. market navigates the aftermath of a record government shutdown, with major indices like the Dow Jones and Nasdaq experiencing fluctuations, investors are paying close attention to sectors that can weather such uncertainties. In this context, growth companies with high insider ownership present an intriguing opportunity, as they often demonstrate strong alignment between management and shareholder interests—a critical factor in navigating volatile market conditions. Nov 13, 2025 - $CV
CapsoVision Reports Third Quarter 2025 Financial Results
SARATOGA, Calif., Nov. 13, 2025 (GLOBE NEWSWIRE) -- CapsoVision, Inc. (NASDAQ: CV), a commercial-stage medical technology company developing advanced imaging and AI-enabled capsule endoscopy solutions, today reported financial results for its third quarter ended September 30, 2025. Recent Highlights Third quarter 2025 revenue was $3.5 million, a 19% increase over the third quarter of 2024.New accounts grew 31% in the third quarter of 2025 over the comparable quarter in 2024.CapsoCam Plus® used b Nov 13, 2025 - $CV
CapsoVision Submits Breakthrough Device Designation Application to FDA for Pancreatic Cancer Screening Capsule
Non-invasive capsule endoscopy system aims to enable earlier detection of pancreatic ductal adenocarcinoma - among the most fatal cancers worldwideSARATOGA, Calif., Nov. 10, 2025 (GLOBE NEWSWIRE) -- CapsoVision, Inc. (NASDAQ: CV), a commercial-stage medical technology company developing advanced imaging and AI-enabled capsule endoscopy solutions, today announced that it has submitted an application to the U.S. Food and Drug Administration (FDA) on November 6, 2025 requesting Breakthrough Device Nov 10, 2025 - $CV
CapsoVision Appoints David Garcia as Senior Vice President of Finance
Seasoned finance executive brings public company, capital markets and transaction experience to support next phase of growthSARATOGA, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) -- CapsoVision, Inc. (NASDAQ: CV), a commercial-stage medical technology company developing advanced imaging and AI-enabled capsule endoscopy solutions, today announced the appointment of David Garcia as Senior Vice President of Finance, effective November 3, 2025. Mr. Garcia brings more than 20 years of financial leadership Nov 3, 2025 - $CV
CapsoVision to Release Third Quarter 2025 Financial Results on Thursday, November 13, 2025
Conference Call Scheduled for Thursday, November 13, 2025 at 4:30 pm ETSARATOGA, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) -- CapsoVision, Inc. (NASDAQ: CV), a commercial-stage medical technology company developing advanced imaging and AI-enabled capsule endoscopy solutions, today announced that the company will release third quarter 2025 financial results on Thursday, November 13, 2025, after the close of market. CapsoVision will host a corresponding conference call and a live webcast at 1:30 pm P Oct 30, 2025 - $CV
CapsoVision to Participate in the 4th Annual ROTH Healthcare Opportunities Conference
SARATOGA, Calif., Sept. 25, 2025 (GLOBE NEWSWIRE) -- CapsoVision, Inc. (NASDAQ: CV), a commercial-stage medical technology company developing advanced imaging and AI-enabled capsule endoscopy solutions, today announced that Johnny Wang, President and Chief Executive Officer, and Doug Atkinson, Head of Global Sales, will participate in the 4th Annual ROTH Healthcare Opportunities Conference, taking place on Thursday, October 9, 2025, in New York, NY. If you are interested in arranging a one-on-on Sep 25, 2025 - $CV
Smart Pills Company Evaluation Report 2025 | Medtronic, Olympus, and CapsoVision Lead with Minimally Invasive and AI-Enhanced Medical Technologies
The 360 Quadrants analysis highlights the leaders in the global Smart Pills market, evaluating over 102 companies. Smart pills, also known as ingestible sensors or digital pills, offer revolutionary diagnostic functions and medication adherence monitoring by transmitting real-time data wirelessly. Key players include Medtronic, Olympus Corporation, and CapsoVision. The market's growth is driven by the demand for less invasive diagnostics and addressing medication non-adherence issues. Challenges Aug 14, 2025 - $CV
CapsoVision Reports Second Quarter 2025 Financial Results
SARATOGA, Calif., Aug. 14, 2025 (GLOBE NEWSWIRE) -- CapsoVision, Inc. (NASDAQ: CV), a commercial-stage medical technology company developing advanced imaging and AI-enabled capsule endoscopy solutions, today reported financial results for its second quarter ended June 30, 2025. Recent Highlights Second quarter 2025 revenue was $3.3 million, a 17% increase over the second quarter of 2024.New accounts grew 75% in the second quarter of 2025 over the comparable quarter in 2024.CapsoCam Plus® used by Aug 14, 2025 - $CV
CapsoVision to Release Second Quarter 2025 Financial Results on Thursday, August 14, 2025
- Conference Call Scheduled for Thursday, August 14, 2025 at 4:30 pm ET - SARATOGA, Calif., July 31, 2025 (GLOBE NEWSWIRE) -- CapsoVision, Inc. (NASDAQ: CV), a commercial-stage medical technology company that develops advanced imaging and artificial intelligence (“AI”) technologies that are deployed in its capsule endoscopy solutions, today announced that the company will release second quarter 2025 financial results on Thursday, August 14, 2025, after the close of market. CapsoVision will host Jul 31, 2025 - $CV
We use cookies and similar technologies to collect and process data such as browsing activity or unique identifiers.
Selecting "Allow All" lets us enhance your experience and provide personalized content and ads.
Choosing "Essential Cookies Only" enables only the cookies necessary for core site functions, such as staying logged in.
For more information, please see our Privacy Policy.
Continue with Google
Continue with Facebook
Continue with Microsoft
Continue with Apple